In patients with EGFR‐mutated stage IB‐IIIA NSCLC, adjuvant osimertinib after full tumor excision dramatically increases DFS and reduces the risk of both local and distant recurrence.265. This evidence concerns the gene EGFR and non-small cell lung carcinoma.